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ABSTRACT 
In the course of our screening program, the EtOAc extract of a Micromonospora sp. (strain 
G044) from sponge Tethya aurantium of the sea of Côtô - Thanh Lân exhibited antimicrobial 
activity against Enterococcus faecalis, Bacillus cereus and Candida albicans. In this paper, we 
reported the isolation and structural elucidation of six secondary metabolites Cyclo-(Pro-Trp) 
(1), Cyclo-(Pro-Met) (2), Cyclo-(Pro-Val) (4), N-acetyltryptamine (3), uridine (5), and 2-
phenylacetic acid (6) from the cultures broth of Micromonospora sp. (strain G044). The 
structures of 1 – 6 were determined by analyses of MS and 2D NMR data. All compounds were 
evaluated for their antimicrobial activity against a panel of clinically significant microorganisms. 
Compound 1 inhibited Escherichia coli with a MIC value of 128 µg/ml.  
Keywords: Micromonospora sp., marine microorganisms, antimicrobial activity, Cyclo-(Pro-
Trp), Cyclo-(Pro-Met), Cyclo-(Pro-Val). 
1. INTRODUCTION 
Sponges have been the focus of many studies as they have proved to be a rich source of 
biologically active secondary metabolites. Since the discovery of spongothymidine and 
spongouridine in the early 50's [1], a large number of biologically active compounds were 
isolated from marine sponges and their associated microorganisms [2]. The chemical diversity of 
sponge-derived products is remarkable and their biological activity ranges from anti-
inflammatory, antitumour, immuno- or neurosuppressive, antiviral, antimalarial, antibiotic to 
antifouling [3]. However, many of the bioactive compounds found in sponges are, in fact, 
produced by their associated microbial communities [4 - 5].  In the course of our screening 
program, the EtOAc extract of a Micromonospora sp. (strain G044) from sponge of the sea of 
Côtô -Thanh Lân exhibited an inhibition activity against Enterococcus faecalis, Bacillus cereus 
and Candida albicans.  In this paper, we reported the isolation and structural elucidation of six 
  




secondary metabolites Cyclo-(Pro-Trp) (1), Cyclo-(Pro-Met) (2), Cyclo-(Pro-Val) (4), N-
acetyltryptamine (3), uridine (5), and 2-phenylacetic acid (6) from the cultures broth of 
Micromonospora sp. (strain G044) (Figure 1). Compound 1 inhibited Escherichia coli with a 
MIC value of 128 µg/ml. 
Figure 1. Compounds (1-6) isolated from the culture broth of Micromonospora sp (G044 strain). 
2. MATERIALS AND METHODS 
2.1. General Experimental procedures 
ESIMS were recorded on an Agilent 1100 LC-MSD Trap spectrometer. NMR spectra were 
recorded on a Bruker 500.13 MHz spectrometer operating at 125.76 MHz for 13C NMR, and at 
500.13 MHz for 1H NMR. 1H chemical shifts were referenced to CDCl3, DMSO-d6 and CD3OD 
at δ 7.27, 2.50 and 3.31 ppm, respectively, while the 13C chemical shifts were referenced to the 
central peak of at δ 77.1 (CDCl3), 39.5 (DMSO-d6), and 49.0 (CD3OD). For HMBC experiments 
the delay (1/2J) was 70 ms. TLC silica gel Merk 60 F254 was used as Thin-layer chromatography. 
Column chromatography (CC) was carried out using silica gel 40 - 63 µm or Sephadex LH-20. 
2.2. Marine Materials 
The samples of sponge Tethya aurantium (Pallas, 1767) were collected in Côtô - Thanh Lân 
in April 2014, and were identified by Prof. Do Cong Thung. Voucher specimens were deposited 
at the Institute of Marine Biochemistry and Institute of Marine Environment and Resources of 
the Vietnam Academy of Science and Technology, Hanoi, Vietnam. 
2.3. Bacteria isolation, fermentation and identification 
The sponge sample (1 g) was added to the 10 mL of sterile sea water in a conical flask. The 
flask was agitated for about one hour. The sponge was filtered and the filtrate was serially 
diluted to obtain 10-1 to 10-7 dilutions using the sterilized sea water. An aliquot of 100 µL of each 
dilution was spread on the media. Different media like starch, yeast extract, peptone agar (A1), 
glycerol asparagine agar (GA Agar), humic acid-B vitamin agar (HV Agar) and glucose yeast 
malt extract agar (GYM) were used for isolation of actinomycetes. The media containing 50 % 
of sterile sea water were supplemented with rifampicin (5 µg/mL) and nystatin (25 µg/mL) 
(Himedia Mumbai) to inhibit bacterial and fungal contamination, respectively. The petriplates 
were incubated upto 3 weeks at 28 °C. The isolated discrete colonies were observed and used for 
identification. The fermentation of Micromonospora sp (strain G044) was cultured in high-
nutrient medium (30 g of instant ocean, 10 g of starch, 4 g of yeast, 2 g of peptone, 1 g of 
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calcium carbonate, 40 mg of iron sulfate, and 100 mg of potassium bromate) for 7 days at 28°C 
while shaking at 200 rpm. Sequencing 16S rRNA method was used for identification of strain 
G044. The 16S rRNA gene sequencing was carried by DNA Analyzer (ABI PRISM 3100, 
Applied Bioscience). Gene sequences were handled by BioEdit v.2.7.5. and compared with 
bacterial 16S rRNA sequences in GeneBank database by NBCI Blast program.  
2.4. Extraction and isolation 
The culture broth (30 L) of Micromonospora sp. (strain G044) was filtered, and then 
extracted with ethyl acetate (15 L x 5 times). The extract was concentrated in vacuo to give 2.0 g 
of ethyl acetate extract. The EtOAc residue was chromatographed on silica gel column, eluted 
with a solvent gradient of CH2Cl2/MeOH (0 to 80 % MeOH in CH2Cl2)  to yield 18 fractions. 
Fraction 7 (0.16 g) was chromatographed on a silica gel CC, eluted with mixtures of 
CH2Cl2/acetone (0 to 50 % acetone in CH2Cl2), to give five subfractions. Subfraction 7.5 was 
subjected to CC on silica gel, eluted with the mixture of CH2Cl2/acetone (95/5) to obtain 6 (6 
mg). Fraction 11 (0.13 g) was subjected to Sephadex LH-20 CC (MeOH) to afford five 
subfractions. Subfraction 11.3 was purified by CC on silica gel, eluted with mixtures of 
CH2Cl2/acetone (95/5) to afford 2 (5 mg). Subfraction 11.5 was purified by CC on silica gel, 
eluted with the mixture of CH2Cl2/EtOAc (6/4) to afford 3 (4 mg) and 1 (8 mg). Fraction 15 was 
subjected to Sephadex LH-20 CC (MeOH) to afford four subfractions, subfraction 15.2 was 
purified by CC on silica gel, eluted with mixtures of CH2Cl2/acetone (9/1) to afford 4 (6 mg). 
Fraction 18 was subjected to Sephadex LH-20 CC (MeOH) to afford seven subfractions. 
Subfraction 18.6 was purified by TLC preparative using mixtures of CH2Cl2/acetone/MeOH 
(9/1/0.1) to afford 5 (3 mg).   
Cyclo-(Pro-Tryp) (1): White solid; ESI-MS: m/z 284.1409 [M-H]+; 1H-NMR (500 MHz, 
CD3OD): δH (ppm) 1.00 (1H, m, Ha-5), 1.52 (1H, m, Ha-4), 1.72 (1H, m, Hb-4), 1.99 (1H, m, Hb-
5); 3.27 (1H, m, Ha-3), 3.33 (1H, m, H-10), 3.48 (2H, m, Hb-3), 4.03 (1H, m, H-6), 4.43 (1H, m, 
H-9), 7.03 (1H, t, J=  8.0 Hz, H-5’), 7.11 (1H, t, J= 8.0 Hz, H-6’), 7.12 (1H, s, H-2’), 7.35 (1H, 
d, J = 8.0 Hz, H-7’), 7.59 (1H, d, J = 8,0 Hz, H-4’); 13C-NMR (150 MHz, CD3OD): δC (ppm) 
22.6 (C-4), 29.1 (C-10), 29.1 (C-5), 45.9 (C-3), 57.2 (C-9), 60.1 (C-6), 109.6 (C-3’), 112.3                
(C-7’), 119.8 (C-4’), 120.0 (C-5’), 122.6 (C-6’), 125.6 (C-2’), 128.7 (C-3’a), 138.0 (C-7’a), 
167.5 (C=O); 170.8 (C=O). 
Cyclo-(Pro-Met) (2): White solid; ESI-MS: m/z 229.10 [M+H]+; 1H-NMR (500 MHz, CDCl3): 
δH (ppm) 1.90 (1H, m, Ha-4), 2.10 (2H, m, CH2-5), 2.11 (1H, m, Hb-4), 2.12 (3H, s, SCH3), 2.37 
(2H, m, CH2-10), 2.68 (2H, t, J = 6.5 Hz, CH2-11),  3.54 (1H, m, Ha-3), 3.61 (1H, m, Hb-3), 4.10 
(1H, m, H-6), 4.42 (1H, m, H-9); 13C-NMR (125 MHz, CDCl3): δC (ppm) 15.3 (SCH3); 22.7 (C-
4), 28.2 (C-5), 28.9 (C-11), 30.3 (C-10), 45.5 (C-3), 54.6 (C-9), 59.0 (C-6), 165.4 (C=O), 170.3 
(C=O). 
2-(3-indolyl) ethylamine acetate (3): White solid; ESI-MS: m/z 203 [M+H]+; 1H-NMR (500 
MHz, CDCl3): δH (ppm) 1.93 (3H, s, COCH3), 2.98 (2H, t, J = 6.5 Hz, CH2-1’), 3.60 (2H, q,             
J = 6.5 Hz, CH2-2’), 7.04 (1H, d, J = 2.0 Hz, H-2), 7.13 (1H, td, J = 1.0, 8.0 Hz, H-5), 7.21 (1H, 
td, J = 1.0, 8.0 Hz, H-6), 7.38 (1H, d, J = 8.0 Hz, H-7), 7.60 (1H, d, J = 8.0 Hz, H-4), 8.16 (1H, 
br s, NH); 13C-NMR (125 MHz, CDCl3): δC (ppm) 23.4 (COCH3), 25.3 (C-1’), 39.8 (C-2’), 
111.3 (C7), 113.0 (C-3), 118.7 (C-4), 119.5 (C-5), 122.0 (C-6), 122.3 (C-2), 127.4 (C-3a), 136.4 
(C-7a), 170.2 (C=O). 
Cyclo-(Pro-Val) (4): White solid; ESI-MS: m/z 197.1[M+H]+; 1H-NMR (500 MHz, CD3OD): 
δH (ppm) 0.95 (3H, d, J = 6.8 Hz, CH3-11), 1.11 (3H, d, J = 6.8 Hz, CH3-12), 1.94 - 2.05 (3H, m, 
  




CH2-4, Ha-5), 2.33 (1H, m, Hb-5), 2.50 (1H, m, H-10), 3.54 (2H, m, H-3), 4.05 (1H, m, H-6), 
4.22 (1H, m, H-9); 13C-NMR (125 MHz, CD3OD): δC (ppm) 15.2 (C-11), 17.4 (C-12), 21.8 (C-
4), 28.1 (C-5), 28.5 (C-10), 44.8 (C-3), 58.6 (C-9), 60.1 (C-6), 166.2 (C=O), 171.2 (C=O). 
Uridine (5): White solid; ESI-MS (m/z): 245.1 [M+H]+. 1H-NMR (500MHz, CD3OD) δ(ppm) 
3.75 (1H, dd, J = 3.0, 12.5 Hz, Ha-5), 3.86 (1H, dd, J = 2.5, 12.5 Hz, H- Hb-5); 4.03 (1H, m, 
H-4), 4.17 (1H, m, H-3), 4.20 (1H, m, H-2), 5.72 (1H, d, J = 8.0 Hz, H-5), 5.92 (1H, d,              
J = 4.5 Hz, H-1), 8.02 (1H, d, J = 8.0 Hz, H-6). 
2-phenylacetic acid (6): White solid. ESI-MS: m/z 136 [M]+. 1H-NMR (500 MHz, CDCl3):     
δH (ppm) 3.69 (2H, s, CH2-7); 7.30 - 7.39 (5H, m, Ph-H). 13C-NMR (125 MHz, CDCl3): δC 
(ppm) 41.4 (C-7), 127.2 (C-4), 128.6 (C-2 and C-6), 129.4 (C-3 and C-5), 133.8 (C-1), 175.2 
(COOH). 
2.5. Antimicrobial assay  
Antimicrobial assays were carried out using E. coli (ATCC25922), P. aeruginosa 
(ATCC27853), S. enterica (ATCC12228), E. faecalis (ATCC13124), S. aureus (ATCC25923), 
B. cereus (ATCC13245), and C. albicans (ATCC1023). Stock solutions of samples were 
prepared in DMSO, and the antimicrobial assays were carried out in 96-well microtiter plates 
against the microbial strains (5 × 105 CFU/mL) using a modification of the published method 
[6]. After incubation for 24 h at 37 °C, the absorbance at 650 nm was measured using a 
microplate reader. Streptomycin and nystatin were used as reference compounds. 
3. RESULTS AND DISCUSSION 
Compound 1 was isolated as a white solid. In its positive HRESI mass spectrum, the pseudo-
molecular ion was observed at m/z 284.1409 [M+H]+, suggesting a molecular formula of 
C16H19N3O2. Analyses of the 13C-NMR and DEPT spectra with the aid of the HSQC of 1 
indicated the presence of 16 carbons, including four sp3 methylenes at δC 22.6 (C-4), 29.1 (C-
10), 29.1 (C-5), 45.9 (C-3), two sp3 methines at δC 57.2 (C-9), 60.1 (C-6), eight aromatic carbons 
(five methines and three quaternary carbons) and two carbonyl carbons at δC 167.4 and 170.3. 
The 1H-NMR spectrum of 1 indicated the presence of a 1,2-disubstituted benzene ring [δH 7.03 
(1H, t, J= 8.0 Hz, H-5’), 7.11 (1H, t, J= 8.0 Hz, H-6’), 7.35 (1H, d, J= 8.0 Hz, H-7’), 7.59 (1H, 
d, J= 8,0 Hz, H-4’)], a singlet aromatic proton at δH 7.12 (1H, s, H-2’), and ten protons in the 
aliphatic region. The chemical shifts of CH-6 (δC 60.7, δH 4.03), CH-9 (δC 57.2, δH 4.42), and 
CH2-3 (δC 45.9, δH 3.27, 3.48) suggested their linkage to nitrogen. Analysis of COSY spectrum 
revealed the presence of three spin – spin coupling systems: CH2-3/CH2-4/CH2-5/CH-6; CH-
9/CH2-10 and H-4’/H-5’/H-6’/H-7’ (Figure 2). These observed data revealed that compound 1 
was a cyclodipeptide compound, forming from a proline and tryptophan units. In the HMBC 
spectrum, the correlation of H-10 with C-2, C-3’, C-9, C3a’and C-1 suggested that the indole 
ring was attached to C-10 (Figure 2). Detailed analysis of 2D NMR spectra, especially HMBC 
spectrum allowed determining the structure of 1 as Cyclo-(Pro-Trp). This cyclodipeptide was 
previously described [5, 7]. 
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Figure 2. Selected COSY ( ) and HMBC ( ) correlations of 1.  
Compound 2 was obtained as a white amorphous solid. The ESI-MS indicated the 
pseudomolecular ion peak at m/z 229.10 [M+H]+. The 1H-NMR spectrum of 2 displayed signals 
of a methyl groups at δH 2.12 (3H, s, SCH3) and signals of 12 aliphatic protons ranging from 
1.90 to 4.42 ppm. Analysis of the 13C NMR and DEPT spectra of 2 revealed the presence of 10 
carbons, including one methyl groups at δC 15.3 (SCH3), two methines at δC 54.6 (C-9), 59.0 (C-
6), five methylenes at δC 22.7 (C-4), 28.2 (C-5), 28.9 (C-11), 30.3 (C-10), 45.5 (C-3), and two 
carbonyl at δC 165.4 (C=O) and 170.3 (C=O). The chemical shifts of CH-6 (δC 59.0, δH 4.10), 
CH-9 (δC 54.6, δH 4.42) and CH2-3 (δC 45.5, δH 3.54 and 3.61) suggested their linkage to 
nitrogen atoms. Detailed analysis of the NMR suggested the structure of 2 which was a 
cyclodipeptide compound, forming from a proline and methionine units. Complete analysis of 
the NMR spectra and comparison with reported NMR data indicated that compound 2 was 
Cyclo-(Pro-Met) [8]. 
Compound 3 was isolated as a white solid. In its positive ESI mass spectrum, the pseudo-
molecular ion was observed at m/z 203 [M+H]+. In the 1H-NMR spectrum, the presence of a 1,2-
disubstituted benzene ring [δH 7.13 (1H, td, J = 1.0, 8.0 Hz, H-5), 7.21 (1H, td, J=  1.0, 8.0 Hz, 
H-6), 7.38 (1H, d, J = 8.0 Hz, H-7), 7.60 (1H, d, J = 8.0 Hz, H-4)], and a singlet aromatic proton 
at δH 7.04 (1H, d, J = 2.0 Hz, H-2) were noted. However, at the aliphatic region of  in the 1H-
NMR of 3, the signals of an acetyl at δH 1.93, a triplet methylene group at δH 2.98  and a quartet 
methylene group bonded with nitrogen at δH 3.60 were observed. The 13C-NMR and DEPT 
spectra of  3 showed signals of the groups observed above with additional signals of a caboxyl 
amide group at δC 170.2 and three quaternany carbone. Complete analysis of the NMR spectra 
and comparison with reported NMR data indicated that compound 3 was 2-(3-indolyl) 
ethylamine acetate [9]. 
Compound 4 was isolated as a white solid. The ESI mass spectrum of 1 presented a base 
peak at m/z 197.1 [M+H]+. In the 13C-NMR spectrum, the some signals of protons at the 
aliphatic region of 4 was close of 1, including one methylene  group attached to nitrogen at δC  
44.8 (C-3), 2 methine sp3 groups bonded with nitrogen at  δC 58.6 (C-9) and δC 60.1 (C- 6), two 
carbonyl amide groups at δC 166.2 (C=O); 171.2 (C=O) and two methylen groups at δC 21.8 (C-
4), 28.1 (C-5). The difference between two compounds was the presence of a -CH(CH3)2 moiety 
of 4 instead of a indole ring of compound 1, this observation was based on 1H-NMR spectra, the 
signals of two doublet methyl groups at 0.95 (3H, d, J=6.8 Hz, CH3-11), 1.11 (3H, d, J = 6.8 Hz, 
CH3-12) and a methine group at 2.50 (1H, m, H-10) instead of the indol ring signals of 1. These 
results suggested 4 belonging to a diketopiperazine compound. NMR-data comparison with 
those previously reported defined compound 4 to be identical with Cyclo-(Pro-Val) [10-11]. 
  




Compound 5 was obtained as a white solid. The ESI mass spectrum of 5 showed a base 
peak at m/z 245.1 [M+H]+. In the 1H-NMR, compound 5 displayed signals of two olefin protons 
at δH 5.72 (1H, d, J= 8.0 Hz, H-5), 8.02 (1H, d, J= 8.0 Hz, H-6) and  a set of the protons of 
arabionoside sugar moiety at δH 3.75 (1H, dd, J=3.0, 12.5 Hz, Ha-5), 3.86 (1H, dd, J = 2.5, 
12.5 Hz, Hb-5); 4.03 (1H, m, H-4); 4.17 (1H, m, H-3 ); 4.20 (1H, m, H-2); 5.92 (1H, d,               
J = 4.5 Hz, H-1). Comparison of the 1H-NMR spectrum and TLC of 5 with uridine which was 
available in our laboratory revealed their similarity. Thus, 5 was determined as uridine [12]. 
Compound 6 was isolated as a white solid. The ESI mass spectrum of 6 presented a base 
peak at m/z 138 [M+H]+. In the 1H-NMR, compound 6 displayed signals of 5 aromatic protons 
at δH 7.30-7.39 (5H, m, Ph-H), one singlet methylene at δH 3.59 (CH2-7’). The 13C-NMR and 
DEPT spectra of 2 indicated the presence of a phenyl ring at δC 127.2-133.8, one methylene 
group at δC 41.4 (C-7) and a carbonyl group at δC 175.2. Complete analysis of NMR spectra and 
comparison with the data reported in the literature allowed determining the structure of 6 to be 
2-phenylacetic acid [13]. 
All the isolates were evaluated for their antibacterial activity against Escherichia coli 
(ATCC25922), Pseudomonas aeruginosa (ATCC27853), Salmonella enterica (ATCC12228), 
Enterococcus faecalis (ATCC13124), Staphylococcus aureus (ATCC25923), Bacillus cereus 
(ATCC13245), and antifungal activity against Candida albicans (ATCC1023). Compounds 1 
selectively inhibited E. coli with MIC value of 128 µg/mL, in comparison with the reference 
compound, streptomycin (MIC: 32 µg/mL). 
4. CONCLUSION 
Six secondary metabolites Cyclo-(Pro-Trp) (1), Cyclo-(Pro-Met) (2), Cyclo-(Pro-Val) (4), 
N-acetyltryptamine (3), uridine (5), and 2-phenylacetic acid (6) were isolated from the cultures 
broth of Micromonospora sp. (strain G044). Compound 1 inhibited Escherichia coli with a MIC 
value of 128 µg/ml. 
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